Formulation Challenges and Process Solutions for Multi-API Oral Dissolvable Films (ODFs)

Introduction
With the growing demand for multifunctional products in both the supplement and pharmaceutical markets, multi-API oral dissolvable films (ODFs) have become an industry hotspot. From vitamin-mineral combination films to drug-excipient synergistic release films, these products face significant challenges in formulation stability, dosage uniformity, and regulatory compliance. To successfully commercialize this dosage form, manufacturers need not only a scientifically designed formulation, but also high-standard equipment that meets both supplement and pharmaceutical-grade GMP requirements.

1. Three Key Formulation Challenges

1. API Compatibility
   Different active ingredients vary greatly in their physicochemical properties, which can lead to degradation, crystallization, discoloration, or other adverse reactions.
2. Differences in Dissolution and Release Rates
   Some ingredients dissolve quickly while others are slower, potentially affecting overall absorption performance.
3. Achieving Uniform Distribution
   Maintaining an even distribution of multiple ingredients in a film only 0.1–0.3 mm thick requires highly precise coating and stable drying processes.

2. Process Solutions

• Multi-formulation Coating Technology – Utilizing dual tanks or multi-channel coating heads to apply different formulations in separate zones, minimizing interference between APIs.
• Stepwise Drying with Temperature Gradients – Preventing ingredient migration or precipitation during drying to maintain content uniformity.
• In-line Quality Monitoring – Equipping the line with thickness measurement and vision inspection systems for full traceability and quality assurance.

3. HUANGHAI’s Equipment Advantages

The HUANGHAI multi-formulation coating system exceeds standard food-grade requirements and fully meets supplement and pharmaceutical-grade GMP standards:

• All materials, design, and cleanability meet pharmaceutical GMP specifications
• Suitable for direct use in drug registration, export filings, and “Blue Hat” supplement registration
• Integrates multi-formulation coating, gradient drying, and in-line inspection in a single solution — proven in both domestic and international pharmaceutical and nutraceutical facilities

Conclusion

Multi-API ODFs represent the synergy of advanced formulation and precision manufacturing. Choosing equipment that meets pharmaceutical-grade compliance not only ensures product quality but also gives companies a competitive edge in global markets.

Explore related equipment: ODF film coating machine | pharmaceutical testing instruments.

Interested in our pharmaceutical equipment? Contact us for a quote.

---

Frequently Asked Questions

Q: What pharmacopoeial standard governs dissolution testing?

A: Dissolution testing is governed by USP <711> (United States Pharmacopeia), ChP 0931 (Chinese Pharmacopoeia), and Ph.Eur. 2.9.3 (European Pharmacopoeia). All Huanghai RCZ-series dissolution testers are designed to comply with USP <711> paddle and basket methods, meeting the ±0.5 rpm speed tolerance and ±0.5°C temperature control requirements. For international market access, verify which pharmacopoeia your target regulatory body recognizes.

Q: How many dissolution channels do I need for a QC lab?

A: Channel selection depends on your batch size and testing throughput. A 6-channel tester (RCZ-6N) suits small-volume labs running one formulation at a time. An 8-channel tester (RCZ-8A) accommodates USP <711> 6-vessel runs with 2 spares. A 12-channel tester (RCZ-12A) is ideal for high-throughput labs running two products simultaneously. As a rule: choose at minimum 8 channels for routine QC; upgrade to 12 if you have more than 3 active products in QC testing. Contact us for pricing.

Q: What is the difference between syringe pump and peristaltic pump in automated sampling?

A: Syringe pumps (used in Huanghai RCZ-QY series) deliver precise, pulsation-free sample withdrawal—critical for viscous media or flow-sensitive APIs. Peristaltic pumps are lower cost but introduce pulsation artifacts that can affect UV absorbance readings in inline detection. For validated methods submitted to regulatory agencies, syringe-pump systems such as the RCZ-QY12 are preferred because they demonstrate superior reproducibility in audit-trail-backed data.

Q: Does the dissolution tester support FDA 21 CFR Part 11 compliance?

A: Huanghai intelligent dissolution testers (RCZ-8N, RCZ-12A, RCZ-QY series) include audit trail functionality—timestamped records of all parameter changes and operator actions—meeting basic USP and ChP audit trail requirements. However, they are not certified as fully 21 CFR Part 11 compliant because certain parameters remain modifiable for R&D flexibility. For FDA-regulated QC environments, pair the instrument with a validated LIMS or laboratory software stack to achieve full Part 11 compliance. Contact us to discuss compliance configuration for your specific regulatory submission.

Q: How often should dissolution media be degassed before testing?

A: USP <711> recommends degassing dissolution media immediately before use to remove dissolved oxygen that can cause bubble formation on tablet surfaces—leading to false-low dissolution results. Best practice: degas each media batch within 30 minutes of testing. The HTQ-1A Vacuum Degasser processes up to 25 liters in a single cycle using vacuum + UV sterilization, eliminating microbial contamination risk. For labs running 8–12 channel testers, a dedicated degasser prevents throughput bottlenecks between runs.